Belite Bio Inc Adr (BLTE)

Sep 09, 2026

Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com

Sep 09, 2026

Sep 09, 2026

Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - Investing.com

Sep 09, 2026

Sep 09, 2026

How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 09, 2026

Sep 09, 2026

Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com Australia

Sep 09, 2026

Sep 09, 2026

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance

Sep 09, 2026

Sep 09, 2026

Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com UK

Sep 09, 2026

Sep 09, 2026

Mizuho raises Belite Bio stock price target on Japan drug filing By Investing.com - Investing.com South Africa

Sep 09, 2026

Sep 08, 2026

Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com Canada

Sep 08, 2026

Sep 08, 2026

Belite Bio files Japan NDA for Stargardt disease drug - grafa.com

Sep 08, 2026

Sep 08, 2026

Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com South Africa

Sep 08, 2026

Sep 08, 2026

Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease - TipRanks

Sep 08, 2026

Sep 08, 2026

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt... - markets.businessinsider.com

Sep 08, 2026

Sep 08, 2026

Belite Bio (NASDAQ: BLTE) seeks Japan OK for Stargardt pill that could be a first - Stock Titan

Sep 08, 2026

Sep 04, 2026

Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com South Africa

Sep 04, 2026

Sep 04, 2026

Belite Bio Pops As Wall Street Backs Stargardt Bet - TipRanks

Sep 04, 2026

Sep 04, 2026

Canaccord initiates Belite Bio stock with buy on Stargardt therapy - Investing.com

Sep 04, 2026

Sep 03, 2026

Belite Bio Surges As Tinlarebant Nears FDA Decision - TipRanks

Sep 03, 2026

Sep 03, 2026

H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Australia

Sep 03, 2026

Sep 03, 2026

H.C. Wainwright reiterates Belite Bio stock rating on commercial plans - Investing.com

Sep 03, 2026

Sep 03, 2026

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - Yahoo Finance

Sep 03, 2026

Sep 02, 2026

Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Barchart.com

Sep 02, 2026

Sep 01, 2026

Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com

Sep 01, 2026

Aug 30, 2026

Trading Systems Reacting to (BLTE) Volatility - Stock Traders Daily

Aug 30, 2026

Aug 21, 2026

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - The Manila Times

Aug 21, 2026

Aug 20, 2026

Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research - MarketBeat

Aug 20, 2026

Aug 16, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 16, 2026

Aug 15, 2026

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

Aug 15, 2026

Aug 14, 2026

Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media

Aug 14, 2026

Aug 14, 2026

Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media

Aug 14, 2026

Aug 14, 2026

Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com

Aug 14, 2026

Aug 14, 2026

Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada

Aug 14, 2026

Aug 14, 2026

Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com

Aug 14, 2026

Aug 14, 2026

Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa

Aug 14, 2026

Aug 14, 2026

Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Canada

Aug 14, 2026

Aug 14, 2026

Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat

Aug 14, 2026

Aug 14, 2026

Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat

Aug 14, 2026

Aug 14, 2026

Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com

Aug 14, 2026

Aug 14, 2026

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat

Aug 13, 2026

Aug 13, 2026

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com Canada

Aug 13, 2026

Aug 13, 2026

Belite Bio Q2 Earnings Call Highlights - Yahoo Finance

Aug 13, 2026

Aug 13, 2026

Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat

Aug 13, 2026

Aug 13, 2026

Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat

Aug 13, 2026

Aug 13, 2026

Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks

Aug 13, 2026

Aug 13, 2026

Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan

Aug 13, 2026

Aug 13, 2026

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times

Aug 13, 2026

Aug 12, 2026

BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan

Aug 12, 2026

Aug 12, 2026

Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks

Aug 12, 2026

Aug 12, 2026

Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria

Aug 12, 2026

Aug 12, 2026

Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com Nigeria

Aug 12, 2026